EA201291303A1 - Композиция с замедленным высвобождением - Google Patents

Композиция с замедленным высвобождением

Info

Publication number
EA201291303A1
EA201291303A1 EA201291303A EA201291303A EA201291303A1 EA 201291303 A1 EA201291303 A1 EA 201291303A1 EA 201291303 A EA201291303 A EA 201291303A EA 201291303 A EA201291303 A EA 201291303A EA 201291303 A1 EA201291303 A1 EA 201291303A1
Authority
EA
Eurasian Patent Office
Prior art keywords
composition
salt
extended period
time
present
Prior art date
Application number
EA201291303A
Other languages
English (en)
Other versions
EA021663B1 (ru
Inventor
Томомити Футо
Хикару Таира
Сейтаро Мидзуками
Наоюки Мурата
Original Assignee
Такеда Фармасьютикал Компани Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201291303(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Такеда Фармасьютикал Компани Лимитед filed Critical Такеда Фармасьютикал Компани Лимитед
Publication of EA201291303A1 publication Critical patent/EA201291303A1/ru
Publication of EA021663B1 publication Critical patent/EA021663B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/005—Processes for mixing polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Изобретение относится к композиции с замедленным высвобождением, содержащей производное метастина и полимер молочной кислоты, имеющий среднемассовую молекулярную массу приблизительно от 5000 до 40000, или его соль. Композиция с замедленным высвобождением по настоящему изобретению медленно и стабильно высвобождает соединение (I) или его соль в течение продолжительного периода времени и демонстрирует медицинские эффекты соединения (I) или его соли в течение продолжительного периода времени. Помимо этого, композиция с замедленным высвобождением по настоящему изобретению, которая улучшает соблюдение пациентом режима и схемы лечения, благодаря уменьшению частоты введений, представляет собой превосходную композицию в качестве клинического лекарственного средства.
EA201291303A 2010-06-25 2011-06-23 Композиция с замедленным высвобождением, способ ее получения и способ лечения рака EA021663B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010144792 2010-06-25
PCT/JP2011/064992 WO2011162413A1 (en) 2010-06-25 2011-06-23 Sustained-release formulation

Publications (2)

Publication Number Publication Date
EA201291303A1 true EA201291303A1 (ru) 2013-04-30
EA021663B1 EA021663B1 (ru) 2015-08-31

Family

ID=44583663

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291303A EA021663B1 (ru) 2010-06-25 2011-06-23 Композиция с замедленным высвобождением, способ ее получения и способ лечения рака

Country Status (24)

Country Link
US (2) US20130210742A1 (ru)
EP (1) EP2585091B1 (ru)
JP (1) JP5838173B2 (ru)
KR (1) KR20130097088A (ru)
CN (1) CN103025343B (ru)
AR (1) AR081980A1 (ru)
AU (1) AU2011270093A1 (ru)
BR (1) BR112012032544A2 (ru)
CA (1) CA2802209C (ru)
CL (1) CL2012003645A1 (ru)
CR (1) CR20120604A (ru)
DO (1) DOP2012000304A (ru)
EA (1) EA021663B1 (ru)
EC (1) ECSP12012350A (ru)
ES (1) ES2513569T3 (ru)
IL (1) IL223266A0 (ru)
MA (1) MA34321B1 (ru)
MX (1) MX2012014265A (ru)
PE (1) PE20130276A1 (ru)
SG (1) SG186070A1 (ru)
TN (1) TN2012000562A1 (ru)
TW (1) TW201204378A (ru)
UY (1) UY33465A (ru)
WO (1) WO2011162413A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
EP3518952A1 (en) 2016-09-30 2019-08-07 Myovant Sciences GmbH Methods of treating female infertility

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
EP1310517B2 (en) * 2000-08-07 2010-11-17 Wako Pure Chemical Industries, Ltd. Lactic acid polymer and process for producing the same
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
CN101528772B (zh) * 2006-10-25 2013-03-13 武田药品工业株式会社 Metastin衍生物及其用途
TWI404726B (zh) * 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
CN101563068B (zh) * 2006-12-18 2013-03-20 武田药品工业株式会社 缓释组合物和其制备方法
JPWO2009131191A1 (ja) * 2008-04-24 2011-08-25 武田薬品工業株式会社 メタスチン誘導体およびその用途
MA32935B1 (fr) * 2008-12-29 2012-01-02 Takeda Pharmaceutical Agent prophylactique/therapeutique pour le cancer
MX2012006441A (es) * 2009-12-22 2012-06-28 Takeda Pharmaceutical Formulacion de liberacion sostenida.

Also Published As

Publication number Publication date
AU2011270093A1 (en) 2013-01-10
US20180243422A1 (en) 2018-08-30
CN103025343A (zh) 2013-04-03
EA021663B1 (ru) 2015-08-31
TW201204378A (en) 2012-02-01
ECSP12012350A (es) 2014-02-28
EP2585091A1 (en) 2013-05-01
CA2802209C (en) 2019-12-31
ES2513569T3 (es) 2014-10-27
EP2585091B1 (en) 2014-09-10
PE20130276A1 (es) 2013-03-20
KR20130097088A (ko) 2013-09-02
BR112012032544A2 (pt) 2016-10-11
SG186070A1 (en) 2013-01-30
JP5838173B2 (ja) 2016-01-06
TN2012000562A1 (en) 2014-04-01
DOP2012000304A (es) 2013-01-31
MX2012014265A (es) 2013-01-18
US20130210742A1 (en) 2013-08-15
IL223266A0 (en) 2013-02-03
CA2802209A1 (en) 2011-12-29
MA34321B1 (fr) 2013-06-01
JP2013530926A (ja) 2013-08-01
CN103025343B (zh) 2015-03-25
UY33465A (es) 2012-01-31
CR20120604A (es) 2013-03-21
WO2011162413A1 (en) 2011-12-29
CL2012003645A1 (es) 2013-04-05
AR081980A1 (es) 2012-10-31

Similar Documents

Publication Publication Date Title
CY1118973T1 (el) Παραγωγα αμιδιου βενζοϊμιδαζολο-καρβοξυλικου οξεος για τη θεραπεια μεταβολικων ή καρδιαγγειακων νοσηματων
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
EA201200318A1 (ru) Гетероциклические оксимы
CY1119730T1 (el) Παραγωγα καρβοξυλικου οξεος πυρρολιδινης ως αγωνιστες του συζευγμενου με πρωτεϊνή-g υποδοχεα 43 (gpr43), φαρμακευτικη συνθεση και μεθοδοι για χρηση στην αντιμετωπιση μεταβολικων διαταραχων
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
EA201390339A1 (ru) Замещенные имидазопиридазины
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201201031A1 (ru) Ингибиторы вируса гепатита с
MX2013007537A (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
BRPI0923300A2 (pt) "derivados de nitrato de cilostazol para o tratamento de doenças vasculares e metabólicas"
EP3404029A3 (en) Pyrimido-pyridazinone compounds and methods and use thereof
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
SV2011003907A (es) Composiciones antimicrobianas
EA201390008A1 (ru) Новые ариламидные производные, обладающие антиандрогенными свойствами
EA201490630A1 (ru) 6-замещенные 3-(хинолин-6-илтио)[1,2,4]триазоло[4,3-a]пиридины в качестве ингибиторов c-met тирозинкиназы
IL212596A (en) Its octanidine or its pharmaceutical salt is combined in a solution with polyalcohol
NZ603465A (en) Antimalarial drug which contains 5-aminolevulinic acid or derivative thereof as active ingredient
UA97396C2 (ru) Фармацевтическая композиция пролонгированного высвобождения, содержащая пасиреотид памоат в микрочастицах
UA114088C2 (xx) Лікарська композиція з пролонгованим вивільненням для ін'єкцій
EA201290372A1 (ru) Композиция с замедленным высвобождением
EA201291303A1 (ru) Композиция с замедленным высвобождением
RU2013108390A (ru) Фармацевтическая композиция для предотвращения периоперационной артериальной гипотензии у человека
EA201491099A1 (ru) Соединение, представляющее собой антагонист лейкотриена b4
EA201390488A1 (ru) Новые агонисты gpr 119

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU